ScreenerHero
ALMAlmirall, S.A.
BME · ES · Healthcare · Drug Manufacturers - Specialty & Generic · almirall.com
10.46EUR+0.77%Mkt Cap: 2.47B $P/E: 37.36

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, a…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap2.47B $
Enterprise Value2.47B $
Revenue (TTM)1.26B $
Gross Profit947.41M $
Net Income (TTM)50.17M $
Revenue/Share5.876 USD
Last Price10.46 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.1K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINES0157097017
Valuation
P/E (Trailing)37.36
P/E (Forward)19.18
PEG1.00
EV/EBITDA10.31
EV/Revenue1.97
P/S1.96
P/B1.48
EPS (TTM)0.28
EPS (Forward)0.54
52W Range
10.246% of range13.98
52W High13.98 EUR
52W Low10.24 EUR
Profitability
Gross Margin78.66%
Oper. Margin13.34%
EBITDA Margin19.05%
Profit Margin4.17%
ROE3.10%
ROA1.97%
Growth
Revenue Growth13.00%
Earnings Growth435.10%
Cash Flow & Leverage
Operating CF189.63M $
CapEx (TTM)149.25M $
FCF Margin6.50%
FCF Yield3.31%
Net Debt8.98M $
Net Debt/EBITDA0.04
Balance Sheet
Debt/Equity0.23
Current Ratio2.31
Quick Ratio1.70
Book Value/Sh7.027 EUR
Cash/Share1.632 EUR
Dividends
Fwd Div Rate0.1900 EUR
Trail. Div Rate0.1870 EUR
Div. Yield1.80%
5Y Avg Yield1.85%
Payout Ratio67.59%
Ex-Div DateMay 14, 2026
Pay Date—
Splits
Last Split47:46
Split DateSep 14, 2020
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.30 EUR
Upside (mean)+36.7%
Target Range11.50 EUR – 17.50 EUR
€11.50+36.7% to mean€17.50
# Analysts12
Ownership
Shares Out.217.61M
Float78.27M
Insiders64.07%
Institutions16.95%
Technical
SMA 5011.08 (-5.6%)
SMA 20012.09 (-13.5%)
Beta0.17
S&P 52W Chg18.16%
Avg Vol (30d)84.02K
Avg Vol (10d)109.39K
Technical Indicators
RSI (14)32.9
MACD-0.2010
MACD Signal-0.1550
MACD Hist.-0.0460
BB Upper11.62 EUR
BB Middle10.87 EUR
BB Lower10.11 EUR
BB Width13.89%
ATR (14)0.2194 EUR
Vol Ratio (20d)1.00x